Internal Medicine, Rheumatology · Greeley, CO
NPI
1245678648
Since 2013
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6767 29th St Fl 2
Greeley, CO, 80634
Phone (970) 652-2333
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
72,664 services
Medicare patients, 2024
427
Average age 72
Drug cost, 2024
$12.6M
5,483 prescriptions
Company payments, 2025
$567
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura N Howe was code J3247 (injection, secukinumab, intravenous, 1 mg), 11,864 times for 12 patients. In total Laura N Howe billed 72,664 services in 48 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3247 Injection, secukinumab, intravenous, 1 mg | Office | 11,864 | 12 | $13.76 | $163K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 6,280 | 16 | $24.92 | $156K |
| Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | Office | 5,922 | 18 | $9.96 | $59K |
| Q5121 Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | Office | 5,414 | 19 | $17.84 | $97K |
| J0897 Injection, denosumab, 1 mg | Office | 3,840 | 44 | $20.24 | $78K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 574 | 329 | $12.35 | $7,090 |
| 99213 Office E&M - Established | Office | 350 | 250 | $61.81 | $22K |
| 99214 Office E&M - Established | Office | 336 | 205 | $90.38 | $30K |
| 96372 Injection Administration | Office | 115 | 54 | $10.61 | $1,220 |
| 96413 Chemotherapy Administration | Office | 106 | 65 | $90.57 | $9,600 |
| 96415 Chemotherapy Administration | Office | 83 | 49 | $19.87 | $1,649 |
| 96365 Intravenous Infusion, Hydration | Office | 48 | 35 | $47.05 | $2,259 |
| 99204 Office E&M - New | Office | 19 | 19 | $115.33 | $2,191 |
| 99203 Office E&M - New | Office | 14 | 14 | $77.08 | $1,079 |
By year: 2022 $1.6M for 107,923 services; 2023 $1.4M for 81,613 services; 2024 $1.1M for 72,664 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laura N Howe prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 624 prescriptions and refills. In total Laura N Howe wrote 5,483 Medicare prescriptions that cost $12.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 624 | 1,588 | 197 | $21K |
| Prednisone Generic | 578 | 1,000 | 192 | $4,469 |
| Leflunomide Generic | 489 | 1,316 | 165 | $33K |
| Hydroxychloroquine Sulfate Generic | 460 | 1,118 | 117 | $23K |
| Humira(Cf) Pen Adalimumab | 256 | 256 | 42 | $2.4M |
| Otezla Apremilast | 251 | 251 | 37 | $1.2M |
| Cosentyx Sensoready (2 Pens) Secukinumab | 195 | 195 | 25 | $1.5M |
| Tramadol Hcl Generic | 195 | 202 | 58 | $938 |
| Sulfasalazine Generic | 194 | 478 | 70 | $8,474 |
| Azathioprine Generic | 129 | 316 | 45 | $8,606 |
| Alendronate Sodium Generic | 123 | 334 | 39 | $774 |
| Rinvoq Upadacitinib | 115 | 125 | 16 | $815K |
| Allopurinol Generic | 114 | 343 | 32 | $1,581 |
| Enbrel Sureclick Etanercept | 111 | 111 | 16 | $806K |
| Celecoxib Generic | 105 | 222 | 34 | $6,372 |
Brand drugs: 1,733 claims; generic drugs: 3,738 claims; opioid claims: 207.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura N Howe $567 ($567 in general payments such as food, travel and fees) from 5 companies. The largest payer was Novartis Pharmaceuticals Corporation with $265.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.